Literature DB >> 10650784

p27 expression correlates with prognosis in patients with hypopharyngeal cancer.

H Mineta1, K Miura, I Suzuki, S Takebayashi, K Misawa, Y Ueda, K Ichimura.   

Abstract

BACKGROUND: Hypopharyngeal cancer is closely associated with smoking, drinking, and malnutrition. Recent findings reveal that carcinogenesis depends on genetic aberrations.
MATERIALS AND METHODS: Eighty-one patients with hypopharyngeal cancer were analyzed for p53, CCND1, and p27, and 72 patients were analyzed for p21, immunohistochemically.
RESULTS: p53 overexpression was found in 70%, CCND1 in 17%, p21 in 29%, and p27 in 32%. The low intensity of p27 expression correlated with poor prognosis, but the level of expression of p53, CCND1, and p21 did not.
CONCLUSION: The immunohistochemical analysis of p27 provides a possible tool in determining the prognosis of patients with hypopharyngeal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10650784

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.

Authors:  Mark J Jameson; Linnea E Taniguchi; Kyle K VanKoevering; Menachem M Stuart; Christian R Francom; Rolando E Mendez; Andrew D Beckler; Hans T Carlson; Christopher Y Thomas; Ashraf A Khalil
Journal:  J Oral Pathol Med       Date:  2012-10-26       Impact factor: 4.253

3.  Status of p53 and p27(KIP1) in Iranian Patients With Oral Squamous Cell Carcinoma.

Authors:  Shahroo Etemad-Moghadam; Amanollah Keyhani; Kamran Yazdani; Mojgan Alaeddini
Journal:  Iran Red Crescent Med J       Date:  2015-10-19       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.